Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyQvia in Multifocal Motor Neuropathy
NCT02885259Unknown
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Human normal immunoglobulin G in multifocal motor neuropathy (MMN). Primary endpoint: Safety measured by anamnesis at 1 year. Status: unknown.
02
Drugs
Human normal immunoglobulin G
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT02885259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885259.